Predicting Drug Toxicity in Humans
Genetic Engineering News
“A major challenge of drug safety testing is that preclinical studies with laboratory animals are not always predictive of human safety,” said Albert P. Li, Ph.D., president and CEO of In Vitro ADMET Laboratories. Dr. Li cited the frequent clinical ………………………….http://www.genengnews.com/gen-articles/predicting-drug-toxicity-in-humans/4815/
NASDAQ
Data was presented at the 53rd annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) held in the US. ALKS 3831 … Encouraged by the positive results of the phase I study, Alkermes expects to initiate a phase II dose-ranging study on ALKS 3831.http://www.nasdaq.com/article/encouraging-data-from-alkermes-analyst-blog-cm249504
Silence Starts Phase Ia/IIb Trial of Cancer Drug as It Looks to Balance Pipeline
Silence Starts Phase Ia/IIb Trial of Cancer Drug as It Looks to Balance Pipeline GenomeWeb If no toxicity is observed, the phase IIa arm of the trial will begin with pancreatic cancer patients receiving the two drugs once a week for three consecutive weeks, with no treatment on the fourth week. This dosing schedule will continue in … http://www.genomeweb.com/rnai/silence-starts-phase-iaiib-trial-cancer-drug-it-looks-balance-pipeline
3 Innovative Biotech Companies With Promising Cancer Therapies
Seeking Alpha
The global, Phase III EPIC trial which compares Iclusig to Novartis’ blockbuster drug Gleevec (imatinib) in patients with newly diagnosed CML, is advancing. The company expects to reach full patient enrollment in the fourth quarter of 2013 …
3 Biopharma Runners With Fuel in the Tank
Investorplace.com
Gilead Sciences (GILD) stock recently set a new all-time high after reporting that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission. The regimen produced a 97% …
Gilead Sciences (GILD) stock recently set a new all-time high after reporting that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission. The regimen produced a 97% response rate, with 93% of trial patients surviving progression-free at the end of two years. CLL, which produces too many mature white cells, is the second most common form of leukemia in the U.S.
http://investorplace.com/2013/05/3-biopharma-runners-with-fuel-in-the-tank/
AstraZeneca plc’s planned buyout of Omthera Pharmaceuticals Inc. to gain Phase III-validated Epanova, the anti-triglyceride therapy based on ultra-pure fish oil, puts the firm at a “distinct commercial advantage” over Amarin Corp. plc, with its recently launched Vascepa (icosapent ethyl), said Decision Resources (DR) analyst Paramjit Narang.
http://www.bioworld.com/content/omthera-fish-oil-drug-hooks-astrazeneca-323m-buyout-0
Bristol Myers Squibb Co. (BMY), Gilead Sciences, Inc. (GILD), Halozyme …
Insider Monkey (blog)
present data on its Phase 3 drug nivolumab, which is closest to reaching the market. (Its FDA approval is expected in late 2014 or early 2015.) Nivolumab has the potential to treat a vast array of cancers. At ASCO, Bristol Myers Squibb Co.
Bristol Myers Squibb Co. (NYSE:BMY) present data on its Phase 3 drug nivolumab, which is closest to reaching the market. (Its FDA approval is expected in late 2014 or early 2015.)
Nivolumab has the potential to treat a vast array of cancers. At ASCO, Bristol Myers Squibb Co. (NYSE:BMY) will be presenting data for a Phase 1 study of nivolumad combined with Yervoy to treat melanoma. In a 52-patient study, patients with advanced melanoma saw an overall tumor shrinkage rate of 40%.
However, the company’s most advanced study with nivolumab is in treating advanced non-small cell lung cancer. There, it produced an overall survival of 9.6 months, which is 30% better than standard-of-care. It’s also produced a 22-month overall survival rate in patients with advanced kidney cancer; compared to 20 months for the current standard of care
EPFL scientists have revealed the mechanism, hidden deep within cell mitochondria, that is responsible for making organisms age. Nematodes treated with antibiotics designed to disrupt this mechanism lived longer and healthier lives.
(Photo Credit: EPFLnews)
Slowing the aging process using only antibiotics
READ ALL AT
| Why is it that within a homogeneous population of the same species, some individuals live three times as long as others? EPFL researchers investigated this question and found the mechanism responsible for aging hidden deep within mitochondria. The were able to dramatically slow aging down in worms by administering antibiotics to the young, achieving a … more… |
liraglutide
Danish pharmaceutical company Novo Nordisk announced plans to re-brand and sell its diabetes drug liraglutide (Victoza) as a weight loss drug for obese people by 2015. Currently, the drug is approved and sold to help regulate insulin production in people living with type 2 diabetes.
